An expert from AstraZeneca will discuss the use of antibody drugs, how they function and the different techniques used to characterize them in the drug development process.
This is the fourth of five events in the Bruker COVID-19 Webinar Series.
During this webinar, Dr. Maurizio Muroni from Astra Zeneca, will deliver an introduction on what antibodies are, their structure and an overview of some of the analytical techniques used for their structural characterization.
Presenters
Scientist
AstraZeneca
Dr. Maurizio Muroni was born in Sardinia where he gained a Laurea in Chimica, from University of Sassari, with a thesis on “Cyclic peptides (D, L alternate): synthesis, conformational analysis and molecular modelling”. Following, he moved to Cardiff where he graduated from a PhD in Biochemistry, Cardiff University – School of Chemistry, with a thesis on “ Rational design of artificial enzymes. After his PhD, Maurizio moved to London for an Industry based post doc between PolyTherics (now Abzena) and the School of Pharmacy, developing mass spectrometric methods for the characterization of PEGylated proteins. After two years he joined PolyTherics as Team Leader of Analytical Chemistry. And from 2014, he has been working at MedImmune/AstraZeneca as scientist working on the characterization of therapeutics protein in the Physiochemical Development team.
Production Partner
Bruker Corporation
Bruker offers preclinical imaging solutions for a broad spectrum of application fields, such as cancer research, neuroimaging and cardiac disease.
Additional Content From Bruker Corporation
Unlocking Your Clinical Understanding of Post-Acute COVID Syndrome (PACS), Patient Recovery, and Risk of Subsequent Disease
Watch this webinar to learn about the metabolic changes during COVID-19 disease, how these can be accurately tracked and how NMR can improve the clinical understanding of Long-COVID.
Cardiac PET/MR Imaging in Small Rodents
Experts provide a comprehensive overview of approaches to address cardiac and respiratory gating in PET and MRI in rodent models.
SmartDriveNMR – The Next Generation of Automation
Bruker experts provide an overview of SmartDrive with a particular focus on the exciting new features. They offer practical examples and demonstrate the newest features and functions live!
Related Content
Rethink your Impurity Analysis Strategy
In this webinar, Dr. Ejvind Mørtz discusses the benefits and applications of mass spectrometry (MS)-based host cell protein (HCP) analysis and why HCP ELISAs are insufficient for documenting product-related impurities. Watch to learn where to apply the assay in a typical process and what you gain from deploying it to your workflow.
Exploring Oligomerization and Stoichiometry of Protein Complexes with MALS: Case Studies from Phage-Bacteria Conflict
Experts discuss the utility of SEC-MALS in characterizing protein oligomerization and how it can complement protein structure determination and prediction tools.
A Novel Approach to Removing Urea from Dialysate: Methods and Validation by Amino Acid Quantification
Dr. Guozheng Shao and Dr. Anna Scott discuss the development of an osmotic membrane for use in a portable dialysis device and its validation using amino acid analysis to quantify urea removal using this novel membrane.